About reMYND
reMYND is a company based in Leuven (Belgium) founded in 2002. reMYND has raised $28.17 million across 4 funding rounds from investors including KU Leuven, BNP Paribas Fortis and PMV. The company has 46 employees as of December 31, 2022. reMYND offers products and services including Alzheimer’s Program, Huntington’s Program, and CRO Services. reMYND operates in a competitive market with competitors including Rheonix, Phoremost, 64x Bio, Nanna Therapeutics and Adaptyv Biosystems, among others.
- Headquarter Leuven, Belgium
- Employees 46 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Remynd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.17 M (USD)
in 4 rounds
-
Latest Funding Round
$14.57 M (USD), Series B
Jan 22, 2021
-
Investors
KU Leuven
& 7 more
-
Employee Count
46
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of reMYND
reMYND offers a comprehensive portfolio of products and services, including Alzheimer’s Program, Huntington’s Program, and CRO Services.
Restores synaptic function and reduces pathology in Alzheimer’s disease.
Targets oxidative stress to restore cortico-striatal transmission.
Assesses experimental treatments in proprietary mouse models.
People of reMYND
Unlock access to complete
Unlock access to complete
Funding Insights of reMYND
reMYND has successfully raised a total of $28.17M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.57 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in reMYND
reMYND has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include KU Leuven, BNP Paribas Fortis and PMV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sustainable investing in conscious consumer, energy transition, and healthy living sectors.
|
Locked | Locked | Locked | |
|
Private equity is directed toward private and public companies.
|
Locked | Locked | Locked | |
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for reMYND
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by reMYND
Investment portfolio details for reMYND
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - reMYND
Detailed financials for reMYND
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Remynd Comparisons
Peer comparison for reMYND
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of reMYND
reMYND operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rheonix, Phoremost, 64x Bio, Nanna Therapeutics and Adaptyv Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instruments for automated molecular assays are developed using disposable cartridges.
|
|
| Locked | Locked | Locked |
Phenotypic screening platform developed to identify drug targets and pathways.
|
|
| Locked | Locked | Locked |
Cell and gene therapies for multiple diseases are developed.
|
|
| Locked | Locked | Locked |
In-vitro directed evolution platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Protein design, synthesis, testing, and validation services are offered.
|
Detailed competitors of reMYND
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Remynd
Complete news archive for reMYND
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about reMYND
reMYND was founded in 2002 and raised its 1st funding round 9 years after it was founded.
reMYND is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.
reMYND is a funded company, having raised a total of $28.17M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at reMYND is 46.
reMYND was founded in 2002 in Leuven, Belgium, within the biotechnology sector. In vivo contract research services are offered using proprietary mouse models for progressive amyloidopathy, tauopathy, and combined APP-TAU conditions. A drug discovery program is pursued, emphasizing small molecule therapeutics for protein-misfolding-related neurodegenerative diseases. The lead candidate is advancing through IND-enabling studies for Alzheimers disease, supported by additional programs for Alzheimers, diabetes, Parkinsons, Huntingtons disease, and amyotrophic lateral sclerosis.
reMYND offers Alzheimer’s Program, Huntington’s Program, and CRO Services.
reMYND has 8 investors. Key investors include KU Leuven, BNP Paribas Fortis, PMV, European Union, and Korys.